Drugs /

chimeric antigen receptor t-cells

Back to Drugs List

Overview

NCI Definition [1]:
Autologous or allogeneic T-lymphocytes that are engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.

Clinical Trials

View Clinical Trials for chimeric antigen receptor t-cells

Chimeric antigen receptor t-cells has been investigated in 16 clinical trials, of which 14 are open and 2 are closed. Of the trials investigating chimeric antigen receptor t-cells, 1 is early phase 1 (1 open), 11 are phase 1 (9 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2/phase 3 (1 open).

CEACAM5 Expression, CEACAM3 Expression, and Carcinoembryonic antigen Expression Positive are the most frequent biomarker inclusion criteria for chimeric antigen receptor t-cells clinical trials.

Hepatocellular carcinoma, multiple myeloma, and acute myeloid leukemia are the most common diseases being investigated in chimeric antigen receptor t-cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Chimeric Antigen Receptor T-Cells
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Chimeric Antigen Receptor T-Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating chimeric antigen receptor t-cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
car-t cell, car t cell, chimeric-antigen receptor t-lymphocytes, chimeric antigen receptor t-cell therapy, car-t cells, car-modified t-cells, car t-cells, car t cells, chimeric antigen receptor t-cells
NCIT ID [1]:
C137999

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.